High-grade serous carcinoma is a type of ovarian cancer. It develops from the epithelial cells on the outer surface of the ovary or the inside of the fallopian tube. For this reason, some pathologists will diagnose high-grade serous carcinoma as ‘tubo-ovarian’ to indicate its possible origin from either organ.
Regardless of where the tumour starts, it often involves both organs at the time of diagnosis. It is common for high-grade serous carcinoma to quickly spread to other organs inside the abdomen and pelvis and to the tissue that lines these organs, called the peritoneum.
The ovaries are part of the female reproductive tract. They are small round organs that are connected to the uterus by the fallopian tubes. The outer surface of the ovaries and the inside of the fallopian tubes are lined by specialized cells called epithelial cells that form a barrier called an epithelium. The tissue below the epithelium is called the stroma.
The diagnosis of high-grade serous carcinoma can also be made after a small sample of tissue is removed in a procedure called a biopsy. In this procedure, a small sample of tissue from the pelvis or abdomen is removed. The ovary itself is not usually biopsied.
Because it often spreads to the peritoneum, high-grade serous carcinoma can also be diagnosed after fluid is removed from the abdominal cavity in a procedure called a fine needle aspiration (FNA). The fluid is then sent to a pathologist who examines the cells in the fluid under the microscope.
For some women, the diagnosis of high-grade serous carcinoma is only made when the entire tumour has been surgically removed and sent to a pathologist for examination. The ovary is usually removed along with the fallopian tube, and uterus.
Your surgeon may request an intraoperative or frozen section consultation from your pathologist. The diagnosis made by your pathologist during the intraoperative consultation can change the type of surgery performed or the treatment offered after the surgery is completed.
After carefully examining your sample tissue under the microscope, your pathologist will attempt to determine where the tumour started even if it has spread to multiple organs. The location where the tumour started is called the primary site.
In some cases, the primary site can be determined and will be included in your report as ovary, fallopian tube, or peritoneum. In many cases, however, your pathologist will not be able to determine where the tumour started and the primary site will be described as tubo-ovarian or ‘other’.
All ovarian tumours are examined to see if there are any holes or tears in the outer surface of the tumour or ovary. The outer surface is referred to as the capsule. The capsule is described as intact if no holes or tears are identified. The capsule is described as ruptured if the outer surface contains any large holes or tears.
This information is important because a capsule that ruptures inside the body may spill cancer cells into the abdominal cavity. A ruptured capsule is associated with a worse prognosis and is used to determine the tumour stage (see Pathologic stage below).
The cancer cells in high-grade serous carcinoma can spread from the ovary to another nearby organ such as the fallopian tube or the ovary on the other side of the body. If cancer cells are seen on the surface of the fallopian tube or ovary, it suggests that they have travelled there from another site. This information is important because a tumour that has spread from one organ to another is given a higher tumour stage (see Pathologic stage below).
The organs inside the abdomen are lined by a thin layer of tissue called the peritoneum. Tissue from the peritoneum is often sent along with the ovaries, fallopian tubes, and uterus so they can be examined by your pathologist for cancer cells.
Cancer cells that have spread from the ovary and have stuck to the surface of the peritoneum are called peritoneal implants. It is common for high-grade serous carcinoma to spread to the peritoneum. Peritoneal implants are associated with a worse prognosis and are used to determine the tumour stage (see Pathologic stage below).
Small samples of tissue are commonly removed in a procedure called a biopsy to see if cancer cells have spread to the pelvis or abdomen. These biopsies which are often called omentum or peritoneum are sent for pathological examination along with the tumour.
Other organs (such as the bladder, small intestine, or large intestine) are not typically removed and sent for pathological examination unless they are directly attached to the tumour. In these cases, your pathologist will examine each organ under the microscope to see if there are any cancer cells attached to those organs. Cancer cells in other organs are used to determine the tumour stage (see Pathologic stage below).
Lymph nodes are small immune organs located throughout the body. Cancer cells can travel from the tumour to a lymph node through lymphatic channels located in and around the tumour. The movement of cancer cells from the tumour to a lymph node is called metastasis.
Your pathologist will carefully examine all lymph nodes for cancer cells. Lymph nodes that contain cancer cells are often called positive while those that do not contain any cancer cells are called negative. Most reports include the total number of lymph nodes examined and the number, if any, that contain cancer cells.
If cancer cells are found in a lymph node, the size of the area involved by cancer will be measured and described in your report.
Cancer cells found in a lymph node are associated with a higher risk that the cancer cells will be found in other lymph nodes or a distant organ such as the lungs. The number of lymph nodes with cancer cells is also used to determine the nodal stage (see Pathologic stage below).
If you were treated with chemotherapy (or other drugs designed to kill cancer cells) prior to surgical removal of the tumour, your pathologist will examine the tumour to determine the percentage of the tumour that is still viable (living tumour cells).
The response will be categorized as follows:
The pathologic stage for high-grade serous carcinoma is based on the TNM staging system, an internationally recognized system originally created by the American Joint Committee on Cancer.
This system uses information about the primary tumour (T), lymph nodes (N), and distant metastatic disease (M) to determine the complete pathologic stage (pTNM). Your pathologist will examine the tissue submitted and give each part a number. In general, a higher number means more advanced disease and a worse prognosis.